Novacyt announces update on strategic review of non-core assets

Novacyt announces update on strategic review of non-core assets NOVAprep® and clinical laboratory enter formal sales process Novacyt to enhance focus on core profitable diagnostic products business

Visit Page

Completion of substantial q16 molecular diagnostics order expands clinical diagnostic reach in fast growing Chinese market

Novacyt q16 order in China Paris, France and Camberley, UK – 6th December 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces it has received another substantial order for Primerdesign’s q16 molecular instruments from a new customer within the fast growing Chinese market. The order for 100 molecular

Visit Page

The following announcement replaces the announcement released on 30 May 2018 at 18:30 (UK time) under RNS number 7508P.

Replacement Announcement – Novacyt 30-11-18

Visit Page